School of Medicine

Showing 1-3 of 3 Results

  • Crystal Mackall

    Crystal Mackall

    Professor of Pediatrics (Hematology/Oncology) and of Medicine

    Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program is focused on using genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, will simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.

  • Robbie Majzner

    Robbie Majzner

    Instructor, Pediatrics - Hematology & Oncology

    Bio Robbie Majzner is an Instructor in the Division of Pediatric Hematology-Oncology at the Stanford University School of Medicine. After graduating with a BA in computer science from Columbia University, Dr. Majzner attended Harvard Medical School where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he began working in the laboratory of Crystal Mackall with the goal of translating the success seen with CD19 chimeric antigen receptor (CAR) T cells to pediatric solid tumors.
    Dr. Majzner has generated novel CAR T cells against anaplastic lymphoma kinase (ALK), B7-H3 (CD276), and GD2. His work on the ALK CAR demonstrated that unlike native T cell receptors, synthetic CARs require high antigen density for in vivo efficacy. Using the gold standard CD19 CAR, he is continuing to probe the contribution of antigen density to CAR efficacy, and has reengineered CARs to function at lower antigen densities. He has also generated and validated a novel CAR against B7-H3, a pan-cancer antigen broadly expressed on pediatric tumors, which demonstrates exciting preclinical activity in pediatric sarcomas and brain tumors. Through his research, he aims to bring advances in cell therapy to children with incurable cancers. Clinically, Dr. Majzner cares for patients with neuroblastoma and other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.

Footer Links:

Stanford Medicine Resources: